Merck & Co, one of the world’s largest pharmaceutical companies, announced that it had developed the world’s first coronavirus pill, Molnupiravir, as a result of a cooperation with the company called Ridgeback Biotherapeutics. The company, which took a new step shortly after this announcement, requested urgent use approval to start the use of the drug. Now, there has been a new development regarding Molnupiravir.
The UK Pharmaceuticals and Healthcare Products Regulatory Board has announced that Molnupiravir has been approved for use. The statement means that a brand new era has begun in the fight against the coronavirus pandemic. Because, thanks to this drug, people who have a positive COVID-19 test will be able to overcome the disease without being hospitalized or being taken to intensive care.
Studies on the drug will continue
In the statements made by the British authorities, explanations about the use of the drug were also made. In this context; They recommended that molnupiravir should be used within the first 5 days of symptoms onset. However, the British government and health authorities announced that work will continue for a final decision. It is expected that the work to be done will be completed as soon as possible and that the use of the drug will be shared with the British public.
In the statements made about molnupiravir, it was announced that the effectiveness of this drug was 50 percent. Amesh Adalja of the Johns Hopkins Center for Health Security said, “An oral antiviral tablet that can affect the risk of hospitalization to this extent changes the rules of the game.” Let me point out that . . .
56095
